Loading…
Loading…
BSX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for BSX and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BSX and 80,000+ other tickers.
See exactly how BSX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BSX and 80,000+ other tickers.
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to…
AlphaGrep UK Ltd acquired a new position in shares of Boston Scientific Corporation (NYSE: BSX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 22,906 shares of the medical equipment provider's stock, valued at approximately $978,000. Other large investors
BSX's ICVT sales have jumped 15% as coronary therapies gained traction, while new devices and deals could extend its growth momentum.
In the most recent trading session, Boston Scientific (BSX) closed at $46.95, indicating a -2.94% shift from the previous trading day.
Boston Scientific faces a cyberattack, weaker 2026 guidance and business pressures, raising concerns over its outlook and whether investors should exit.
B. Metzler seel. Sohn and Co. AG boosted its holdings in shares of Boston Scientific Corporation (NYSE: BSX) by 25.8% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 333,583 shares of the medical equipment provider's stock after acquiring an additional 68,450